Overview

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Status:
Not yet recruiting
Trial end date:
2025-09-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche